CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH

CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH

ash

3 months
15 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against b-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Patients with multiple myeloma who had received a median of five prior therapies, and for whom standard-of-care treatments were no longer working, had a high response rate when treated with the investigational CAR T-cell therapy JNJ-4528, which targets BCMA, an antigen a protein commonly found on the surface of multiple myeloma cancer cells. Researchers said that JNJ-4528 is a novel CAR T-cell therapy featuring two receptors molecules that bind to BCMA, an antigena protein found on the surface of multiple myeloma cells. JNJ-4528 has a unique CAR T-cell composition in patients, preferentially enriched in CD8 T-cells, which are believed to be one of the most important T-cells in killing cancer cells.

Up Next Autoplay